Background. True allergy to penicillin is rare, despite the high frequency with which it is reported. Misrepresented allergy drives unnecessary use of alternative antibiotics which may be less effective, more toxic, and more expensive than the penicillins. While most patients reporting penicillin allergy are not prone to anaphylaxis, it is not currently known what percentage of these patients go on to fully tolerate systemic doses of penicillin-based antibiotics. This review aims to determine the tolerance rate in patients with non-anaphylactic penicillin allergy when challenged with systemic doses of penicillin-based antibiotics.
Background. True allergy to penicillin is rare, despite the high frequency with which it is reported. Misrepresented allergy drives unnecessary use of alternative antibiotics which may be less effective, more toxic, and more expensive than the penicillins. While most patients reporting penicillin allergy are not prone to anaphylaxis, it is not currently known what percentage of these patients go on to fully tolerate systemic doses of penicillin-based antibiotics. This review aims to determine the tolerance rate in patients with non-anaphylactic penicillin allergy when challenged with systemic doses of penicillin-based antibiotics.
Methods. We searched MedLine, Embase, and Cochrane Library for publications with English language translations between the years 2000 and 2017. We included controlled trials, quasi-experimental, and observational studies of reportedly penicillin-allergic subjects who received at least one systemic dose of a penicillin in the form of a challenge. At least two independent reviewers extracted data from included studies, and assessed the quality of each included study. To generate primary outcome data, we calculated a summary estimate rate of penicillin tolerance from a pooled fraction of subjects receiving a penicillin with no adverse effects, among all subjects receiving a penicillin challenge.
Results. Initial literature search yielded 5,554 studies, of which 22 studies were ultimately included in our review. A total of 4,572 study participants, each with a history of penicillin allergy low risk for anaphylaxis, were challenged with systemic dosing of a penicillin. After weighting for sample size, an average of 94.8% [95% CI 93.3%, 96.3%] of these patients tolerated penicillin challenge without any adverse reaction.
Conclusion. In addressing the problem of penicillin allergy over-diagnosis, evaluation should go beyond risk for type 1 hypersensitivity. Our data suggest that 94.8% of 4,572 subjects with reported penicillin allergy determined to be low risk for anaphylaxis tolerated repeat administration of penicillin-based antibiotics without any adverse reactions. This review generates meaningful information useful to clinical predictive analytics, in evaluating and managing patients with a reported history of penicillin allergy.
Disclosures. All authors: No reported disclosures. Background. The UNC Medical Center Outpatient Parenteral Antimicrobial Therapy (OPAT) program was started in 2015 to provide multidisciplinary monitoring and management of patients discharged on parenteral antimicrobials. Laboratory abnormalities are a frequent complication of antimicrobial therapy, as are drug reactions such as rash and diarrhea. We examined characteristics of incident adverse drug reactions (ADRs) observed among patients receiving parenteral vancomycin therapy over a two year period.
Vancomycin Treatment and Time to Adverse Drug Reactions During
Methods. This was a retrospective cohort study of patients enrolled in the UNC OPAT program who received vancomycin July 2015-August 2017. Patients with endstage renal disease receiving hemodialysis were excluded. The primary outcome was time-to-first ADR during the first 42 days of vancomycin therapy, estimated using Kaplan-Meier methods. Secondary outcomes included type of ADR and time-to-first nephrotoxicity ADR (>50% increase in serum creatinine). We also assessed indication for OPAT, comorbidities, and concomitant medications among patients with an ADR.
Results. One hundred sixteen patients were followed on vancomycin therapy for 3,367 person-days (~111 person-months). Risk of any ADR within the first 42 days of vancomycin therapy was 33% (95% CI 24%-42%) ( Figure 1) ; risk increased steadily by 6%-8% during the first 4 weeks on vancomycin therapy. The 42-day risk of nephrotoxicity was 18% (95% CI 10%-26%) (Figure 1) , and followed a similar trajectory to overall ADR risks over time on OPAT. Other ADR risks (%) were: neutropenia (<1,000 cells/mm 3 ), 5%; rash, 4%; thrombocytopenia (<100 × 10 3 cells/mm 3 and decrease >50%), 2%; and other, 7%. The most common indications for OPAT vancomycin were osteomyelitis (53%), joint infection (16%), and bacteremia (10%). The most common comorbidities were hypertension (54%) and diabetes (40%). Among patients who experienced an ADR, the most frequent concomitant medications included: NSAID, 62%; ertapenem, 27%; ACE-I, 24%; loop diuretic, 17%; and ARB, 12%.
Conclusion. Risk of ADR increases with duration of parenteral vancomycin therapy during OPAT. Nephrotoxicity was the most common type of ADR during vancomycin therapy. Use of concomitant nephrotoxins during OPAT vancomycin therapy should be evaluated.
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No reported disclosures. Saturday, October 6, 2018: 12:30 PM Background. Ceftolozane/tazobactam (C/T) is indicated for complicated intra-abdominal infections and complicated urinary tract infections (cUTI). Its spectrum of activity extends to most Gram-negative bacteria including multidrug-resistant (MDR) Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing enterobacteriaceae. Current dosing requires 8-hour intervals in order to meet appropriate concentrations above the MIC, making outpatient delivery logistically difficult. C/T is stable up to 24 hours at room temperature, allowing for potential continuous infusion. This study evaluated patients who received this novel dosing regimen at an outpatient infusion center.
Evaluation of Safety and Effectiveness of Continuous Infusion
Methods. This study was a nonrandomized, retrospective chart review of adult patients who received C/T August 2016-January 2018 for any indication, including off-label, in the outpatient setting as a continuous infusion. Primary outcome evaluated was symptom resolution at the end of therapy documented in outpatient records. Secondary outcomes were microbiologic resolution at the end of therapy, if available, and patient satisfaction via a modified patient satisfaction survey assessed from follow-up phone call to patient.
Results. Seven patients received C/T in the outpatient setting and were included in the study. Infections treated varied and included pneumonia (three), cUTI (two), skin and soft tissue (one), and bacteremia (one). Most patients received 4.5 g (with one receiving 9 g) C/T over 24 hours mixed with normal saline via an ambulatory infusion
